共查询到20条相似文献，搜索用时 671 毫秒
1.
2.
2008年从湖北省分离到1株H3N8亚型马流感病毒A/equine/Hubei/6/08。以2002年美国KENTUKY株为模板设计HA基因测序引物,进行RT-PCR,然后测定该分离株的HA基因核苷酸序列。经NCBI上Blast同源性比较发现,与A/equine/Newmarket/5/2003(H3N8)同源性较高为98.7%。HA蛋白遗传进化分析表明该毒株隶属于H3N8亚型马流感病毒中的美洲系福罗里达亚系。该株与OIE现在推荐的疫苗候选株A/equine/Kentuck-y/5/2002(H3N8)HA1蛋白氨基酸序列比对发现有3处氨基酸替换位点;与OIE以往推荐的疫苗候选株A/e-quine/Kentucky/1/1994(H3N8)比对发现有11处氨基酸替换位点。研究结果表明该分离株可作为中国研制马流感疫苗的候选株。 相似文献
3.
《中国兽医学报》2015,(9)
2013年8月某养马厂出现疑似马流感疫情,经分离鉴定为H3N8亚型马流感病毒。为了了解该H3N8马流感分离株(A/equine/Xuzhou/01/2013(H3N8))的基因进化情况,本试验比较了该病毒株,我国已报道的H3N8马流感毒株以及目前全球所使用的疫苗株的病毒基因型,也比较了与抗原性相关的氨基酸的变化情况,为科学防控马流感提供参考依据。采集病死马的内脏样本,进行了A型禽流感病毒通用荧光RT-PCR检测,将荧光RT-PCR检测阳性样品处理后接种鸡胚尿囊腔,检测分离毒尿囊液血凝性及HA效价。参照已发表的扩增H3N8马流感病毒全基因引物,经RT-PCR扩增出该H3N8亚型马流感病毒(A/equine/Xuzhou/01/2013(H3N8))的8个基因片段,对其测序构建基因进化树,并进行分子特征分析。经过比较分析,该病毒株的HA基因在遗传进化上属于佛罗里达Ⅱ型马流感病毒,其余7个片段都属于马流感病毒中的美洲型。在5个公认的抗原位点中,A/equine/Xuzhou/01/2013与我国2007年的分离株(A/donkey/Xinjiang/2007),目前的疫苗株(Miami/63,Kentucky/81,Suffolk/89,Newmarket/2/93和Avesta/93)相比均发生了一些位点的变异。我国H3N8亚型马流感病毒存在抗原变异,需要进一步对其致病性、免疫原性等特性进行研究,同时还需加强马流感病毒分子流行病学监测。 相似文献
4.
马流感能引起马属动物的高度接触性呼吸道传染病。该病毒已知仅存在H7N7(马流感病毒1型)、H3N8(马流感病毒2型)两个亚型,目前仅H3N8亚型毒株在全球范围内引起马流感流行和暴发。采用A型及H3亚型特异性RT-PCR技术,检测云南疑似马流感病例鼻腔棉拭子样品;HA基因PCR扩增产物经纯化后,克隆至pMD18-T载体进行测序,并与已知代表性毒株对应序列进行比对及系统发育分析。研究发现云南马流感病毒与已知代表毒株血凝素基因核苷酸及氨基酸序列同源性分别介于91.2%~99.2%和89.5%~98.4%,属于美洲谱系(American lineage)佛罗里达亚谱系(Florida sub-lineage)毒株。 相似文献
5.
为进一步分析H7N2禽流感病毒（AIV）分离株血凝素（HA）基因的特性,参照已发表序列设计了1对引物,采用RT-PCR获得了1条约1.7 kb的DNA片段,测序后进行了同源性比较、HA基因系统发育进化树分析和氨基酸编码分析.结果表明,所测的2个分离株的HA基因全长1 664 bp,编码除信号肽以外的HA蛋白的全部544个氨基酸,其中包括HA1的323个氨基酸,HA2的221个氨基酸.2个分离株HA基因核苷酸序列的同源性为99.4%;与GenBank中AIV标准株A/Afri.Star./Eng-Q/983/79（H7N1）的同源性最高,分别为99.4%和99.0%;与美国A/Chicken/NewYork/13142-5/94（H7N2）株同源性很低（仅65.0%）,而与以色列、意大利H7N2 AIV的同源性较高（为96%～97%）;2个分离株在HA基因进化树中均处于H7亚型AIV的欧亚群系分支内.推导氨基酸的序列分析表明,其HA蛋白裂解位点的氨基酸序列为-GR-GLF-,仅包含1个碱性氨基酸（R-）残基,符合低致病力AIV的基因特征. 相似文献
6.
从广东省不同猪场分离到4株H3N2亚型猪源流感病毒A/Swine/Guangdong/01/2004、A/Swine/Guang-dong/02/2004、A/Swine/Guangdong/03/2004、A/Swine/Guangdong/04/2004.根据GenBank公布的H3N2亚型猪源流感病毒的HA基因序列,设计1对引物,运用RT-PCR方法扩增四株病毒的HA基因,并进行测序和分析.同源性分析和遗传进化分析表明本实验的4株H3N2亚型SIV HA基因核苷酸序列同源性为99.8%～99.9%,在遗传进化树中均位于同一分支上.与参考毒株的比较分析表明,4个毒株与WHO推荐的2001-2004年北半球H3N2亚型流感疫苗株A/Moscow/10/99 HA基因的核苷酸序列同源性最高为99.4%～99.5%,4个毒株与A/Moscow/10/99 HA基因在遗传进化树中位于同一个小分支上.氨基酸序列比较发现,4个毒株HA基因裂解位点处的氨基酸序列均为PEKQTR↓G,4个毒株推导的氨基酸序列中均有11个糖基化位点,4个毒株HA蛋白226位受体结合位点(RBS)处氨基酸均为异亮氨酸(Ⅰ).4个毒株HA基因的氨基酸序列、受体结合位点以及糖基化位点均与A/Moscow/10/99相应的氨基酸序列一致.本试验的4株H3N2亚型猪源流感病毒的HA基因属于以A/Moscow/10/99为代表的近代类人H3N2亚型流感病毒,在一定程度上揭示了广东省H3N2亚型猪流感病毒HA基因进化与流行情况. 相似文献
7.
为进一步分析禽流感病毒(AIV)H5N2分离株血凝素(HA)基因的特性,参照已发表H5亚型禽流感HA基因序列设计了1对引物,采用RT-PCR技术,以禽流感病毒A/Ostrich/Denmark/72420/96(D96)RNA为模板,扩增了HA全基因并进行核苷酸同源性比较,氨基酸编码分析,绘制系统发育进化树。结果表明,扩增片段长1737个核苷酸,包含了完整的HA基因的开放阅读框架,与Genbank已发表的H5N1和H5N2分离株的HA基因序列比较,发现与国内H5N1分离株同源性较低,只有80%左右,而与H5N2各株序列具有很高的同源性,最高达97.5%,印证了AIV基因组8个片段间频繁的重组及AIV高变异性的特点。推导的氨基酸序列分析表明,HA蛋白裂解位点上游丢失了4个连续碱性氨基酸(R-R-R-K),裂解位点处氨基酸序列为E-T-R,仅包含一个碱性氨基酸(R-)残基,符合低致病性毒株的特征,证明为低致病性毒株。其HA推导后氨基酸序列与H5N1AIV的同源性接近90%,以其研究的疫苗,可以有效抵御我国流行的H5亚型AIV病毒的感染,同时因为是弱毒株,以其研制的疫苗具有更好的安全性,也更符合公共卫生学的要求。 相似文献
8.
3株H9N2亚型禽流感病毒HA基因变异分析 总被引：2，自引：0，他引：2
对近10年来在同一地区分离到的3株H9N2亚型禽流感病毒血凝素(HA)基因进行扩增和序列分析,探讨H9N2亚型流感病毒变异情况.3个毒株的HA基因全长1 683bp,编码560个氨基酸;其裂解位点均为R-S-S-R,属于低致病力毒株;推导的HA基因氨基酸序列均含7个相同的潜在糖基化位点,受体结合位点为禽源性流感病毒特异性序列,左侧臂氨基酸均为NGQQG,右侧臂均为GTSKA.3个分离株与参考株核苷酸与氨基酸同源率均较高,仅有一些非关键位点突变.它们均属欧亚种系,与A/Duck/Hong Kong/Y280/97代表株亲源关系较近.研究结果从分子水平上证明H9N2亚型禽流感病毒近年来未发生较大变异. 相似文献
9.
禽流感病毒A/Chicken/Yangzhou/N/2005(H9N2)HA基因的克隆及序列分析 总被引：1，自引：0，他引：1
根据GenBank公开发表的H9N2型禽流感病毒血凝素(HA)基因序列设计1对引物,用RT-PCR方法成功扩增出H9N2型禽流感病毒分离株A/Chicken/Yangzhou/N/2005(H9N2)HA基因,凝胶电泳结果显示,扩增产物为1.7 kb的单一条带,与预期结果相符.将PCR扩增片段连接到pCR2.1-T载体上,重组质粒酶切鉴定正确.序列测定分析结果显示,所获序列与GenBank中收录的H9N2亚型分离株核苷酸同源性最高达99%,与原型毒株A/Furkey/Wisconsin/1/1966(H9N2)氨基酸同源性为89%.对HA裂解位点附近的氨基酸序列分析表明,此毒株为低致病力毒株. 相似文献
10.
一株禽源高致病性H7N9亚型流感病毒分子特性研究 总被引：1，自引：0，他引：1
为了研究一株禽源高致病性H7N9亚型流感病毒,分析其变异进化及部分生物学特性,试验以从H7N9亚型流感病毒阳性病死鸡的肺脏组织中提取的总RNA为模板,利用特异性引物扩增出全基因序列,分析其核苷酸和氨基酸序列,利用同源建模在线服务软件SWISS-MODEL对突变位点附近的氨基酸序列空间结构进行研究。结果表明:PCR扩增出H7N9亚型流感病毒8个基因片段,即HA、NA、PA、PB1、PB2、NP、NS、M,这8个基因片段均与A/Chicken/Heinan/ZZ01/2017(H7N9)的相应片段具有较高的同源性; HA的第135,226位和NA第401,429位氨基酸存在突变;除A135V突变外,L226Q、A401T、K429R突变均能导致受体结合位点或唾液酸结合位点体积的改变。说明根据基因同源性分析结果,黑龙江省的H7N9流感疫情可能是从中国中部地区传播而来;根据受体结合位点的分析结果,L226Q、A401T和K429R突变可能影响病毒与宿主细胞间的相互作用。 相似文献
11.
It has been recommended that modern equine influenza vaccines should contain an A/equi-1 strain and A/equi-2 strains of the American and European-like subtype. We describe here the efficacy of a modern updated inactivated equine influenza-herpesvirus combination vaccine against challenge with a recent American-like isolate of equine influenza (A/equine-2/Kentucky/95 (H3N8). The vaccine contains inactivated Influenza strains A-equine-1/Prague'56, A-equine-2/Newmarket-1/'93 (American lineage) and A-equine-2/ Newmarket-2/93 (Eurasian lineage) and inactivated EHV-1 strain RacH and EHV-4 strain V2252. It is adjuvanted with alhydrogel and an immunostim. Horses were vaccinated at the start of the study and 4 weeks later. Four, six and eight weeks after the first vaccination high anti-influenza antibody titres were found in vaccinated horses, whereas at the start of the study all horses were seronegative. After the challenge, carried out at 8 weeks after the first vaccination, nasal swabs were taken, rectal temperatures were measured and clinical signs were monitored for 14 days. In contrast to unvaccinated control horses, vaccinated animals shed hardly any virus after challenge, and the appearance of clinical signs of influenza such as nasal discharge, coughing and fever were reduced in the vaccinated animals. Based on these observations, it was concluded that the vaccine protected against clinical signs of influenza and, more importantly, against virus excretion induced by an American-like challenge virus strain. In a second experiment the duration of the immunity induced by this vaccine was assessed serologically. Horses were vaccinated at the start of the study and 6 and 32 weeks later. Anti-influenza antibody titres were determined in bloodsamples taken at the first vaccination, and 2, 6, 8, 14, 19, 28, 32, 37, 41, 45 and 58 weeks after the first vaccination. Vaccinated horses had high anti-influenza antibody titres, above the level for clinical protection against influenza, against all strains present in the vaccine until 26 weeks after the third vaccination. 相似文献
12.
Effect of influenza A/equine/H3N8 virus isolate variation on the measurement of equine antibody responses. 
下载免费PDF全文
下载免费PDF全文 J R Bogdan P S Morley H G Townsend D M Haines 《Canadian journal of veterinary research》1993,57(2):126-130
This study has tested the effect of using homologous or heterologous equine influenza A virus isolates to evaluate serum antibody levels to influenza A virus in vaccinated and naturally-infected horses. In addition, the potential effect of antigenic selection of virus variants in egg versus tissue culture propagation systems was studied. Serum antibody levels in samples from horses recently infected with a local influenza A virus isolate (A/equine 2/Saskatoon/1/90) or recently vaccinated with a prototype isolate (A/equine 2/Miami/1/63) were assessed by hemagglutination inhibition and by single radial hemolysis using cell or egg-propagated A/equine 2/Saskatoon/1/90, A/equine 2/Miami/1/63 or A/equine 2/Fontainebleau/1/79. There were no significant differences in hemagglutination inhibition or single radial hemolysis antibody levels obtained with homologous or heterologous isolates or between viruses propagated in either eggs or cell culture. However there was a trend to higher titers in the hemagglutination inhibition assay when cell-propagated virus was used. These results suggest that antigenic variation in equine influenza A virus isolates and host-cell selection of antigenic variants during virus propagation may not be of sufficient magnitude to influence serological evaluation of antibody responses by hemagglutination inhibition or single radial hemolysis. 相似文献
13.
I. Donatelli M.R. Castrucci L. Campitelli A. Ruggieri L. Sidoli C. Buonavoglia 《Comparative immunology, microbiology and infectious diseases》1991,14(4):315-323
In Italy epizootics of equine influenza often occur, but no virus isolation has been reported since 1971. This paper describes the antigenic and biochemical characterization of two equine influenza viruses isolated in Italy from 1985 to 1989. The virus isolates were shown to differ antigenically from earlier strains of the same subtype, A/equine/Miami/1/63 (H3N8). Monoclonal antibody analysis showed that the haemagglutinins of these strains were serologically indistinguishable from A/equine/Fontainebleau/1/79, a variant of A/equine/Miami, never isolated in Italy before. One of the two virus isolates was obtained from a horse immunized with a bivalent inactivated influenza vaccine, not containing A/equine/Fontainebleau/79 antigens.
The vaccine failure underlines the importance of antigenic relatedness between currently circulating viruses and vaccine strains. Therefore, to improve the protection afforded by equine immunization, the vaccine composition should be decided according to the results of a virological surveillance activity, systematically conducted among horses. 相似文献
14.
William P. Higgins DVM PhD James H. Gillespie VMD Douglas S. Robson PhD 《Journal of Equine Veterinary Science》1987,7(4)
Serum and colostrum were collected from 50 mares at parturition. Pre- and post-nursing serum samples were obtained from their foals. Bi-weekly serum samples were obtained from 25 of the foals for eight weeks. Hemagglutination-inhibiting (HAI) antibody titers to equine influenza viruses A1 and A2 (EIVA1 and EIVA2) and serum-neutralizing antibody titers to equine herpes virus 1 (EHV1) were measured in serum and colostrum samples. IgG levels in serum and colostrum were determined.No antibody was detected in any foal's pre-nursing serum sample. Foal post-nursing antibody and IgG levels were equivalent to those measured in their dam's sera (EHVA1 p=0.86; EHVA2 p=0.54; EHV1 p=0.91; IgG p=0.58). The half-life of maternally-acquired serum antibody in the foals was determined to be: EIVA1=28.88 days (26.4 to 31.7 days); EIVA2=29.1 days (26.7 to 32.1 days); EHV1=31.0 days (28.1 to 34.8 days). Colostrum contained antibody and IgG at levels ranging from 2 to 8 times higher (4.3 average) than those detected in the mare's serum. 相似文献
15.
The aim of this study was to characterise CD4+T-cells in equines, as these cells are pivotal in establishing immune responses or regulating established ones. Peripheral blood mononuclear cells from a pony immunised with ovalbumin were cultured in vitro in the presence of the specific antigen and autologous antigen presenting cells. During the antigen starvation phase, cells were maintained on recombinant equine IL-2. After 35 days of culture, most of the cells were CD4+, CD8-and sIg-. Cells proliferated specifically in the presence of antigen, as tested on day 42 of culture. These cells were analysed by in-situ hybridisation to detect m RNA for IL-2 and IL-4, the presence of which suggested the existence of of Th1- and Th2-like cells. 相似文献
16.
17.
K DYNON A VARRASSO N FICORILLI SA HOLLOWAY GH REUBEL F LI CA HARTLEY MJ STUDDERT HE DRUMMER 《Australian veterinary journal》2001,79(10):695-702
OBJECTIVE: To develop rapid (< 8 hour) tests using polymerase chain reaction (PCR) for the diagnosis of equine herpesvirus 3 (EHV3; equine coital exanthema virus), equine gammaherpesviruses 2 (EHV2) and EHV5, equine adenovirus 1 (EAdV1), EAdV2, equine arteritis virus (EAV), equine rhinitis A virus (ERAV; formerly equine rhinovirus 1) DESIGN: Either single round or second round (seminested) PCRs were developed and validated. METHODS: Oligonucleotide primers were designed that were specific for each virus, PCR conditions were defined and the specificity and sensitivity of the assays were determined. The application of the tests was validated using a number of independent virus isolates for most of the viruses studied. The PCRs were applied directly to clinical samples where samples were available. RESULTS: We developed a single round PCR for the diagnosis of EHV3, a seminested PCR for EHV2 and single round PCRs for EHV5, EAdV1, EAdV2 and RT-PCRs for EAV and ERAV. The PCR primer sets for each virus were designed and shown to be highly specific (did not amplify any recognised non-target template) and sensitive (detection of minimal amounts of virus) and, where multiple virus isolates were available all isolates were detected. CONCLUSION: The development and validation of a comprehensive panel of PCR diagnostic tests, predominantly for viruses causing equine respiratory disease, that can be completed within 8 hours from receipt of clinical samples, provides a major advance in the rapid diagnosis or exclusion diagnosis of these endemic equine virus diseases in Australia. 相似文献
18.
Alternative vaccination against equine botulism (BoNT/C) 总被引：1，自引：0，他引：1
Frey J Eberle S Stahl C Mazuet C Popoff M Schatzmann E Gerber V Dungu B Straub R 《Equine veterinary journal》2007,39(6):516-520
REASON FOR PERFORMING STUDY: In Europe the incidence of botulism in horses has increased in the last decade due to the growing popularity of haylage feeding. Recombinant vaccines are safer and less expensive to produce and are generally better tolerated than toxoids. OBJECTIVES: To investigate whether the recombinant C-terminal half of the heavy chain of the botulinum neurotoxin C (Hc BoNT/C) in combination with an immunstimulatory adjuvant is an appropriate vaccine candidate for horses by testing its efficacy to induce neutralising antibodies and by comparing its immunogenic properties and adverse reactions to a commercial toxoid vaccine. Formation of oedema and local pain reactions were assessed. ELISA and Western blot assay against Hc BoNT/C and testing of neutralising antibody induction in a mouse protection assay were used to evaluate the immune response. RESULTS: With the recombinant vaccine, only minor local swelling with full recovery after 5 days was noted after brisket injections. The toxoid vaccine produced local, painful reactions with longer recovery periods of up to 2 weeks. Horses vaccinated with either vaccine induced neutralising antibodies after the second booster vaccination, while seroconversion on ELISA and Western blot to Hc BoNT/C was apparent after the first recombinant vaccination, and at various time points in the vaccination schedule in horses that received commercial toxoid vaccine. CONCLUSION: The recombinant vaccine showed fewer adverse reactions compared to the only commercially available vaccine but induced similar concentrations of neutralising antibodies. There was no correlation between the serological response to Hc BoNT/C and the neutralising capacity of serum. POTENTIAL RELEVANCE: Recombinant Hc BoNT/C is an appropriate vaccine candidate to stimulate production of neutralising antibodies against botulinum neurotoxin C in horses and creates only minor local reactions at the injection site. 相似文献
19.